FRAZER, Pa. A biopharmaceutical company announced the resignation of one of its executives.
Cephalon said that Robert Roche, EVP worldwide pharmaceutical operations, will resign from his post Feb. 5, 2010, to pursue other longstanding interests. During his tenure, Roche established and grew the Cephalon sales and marketing organization into a global business that exceeded $2 billion in annual sales revenue.
The company will announce plans for its leadership and the commercial organization in the near future.
"Bob Roche made a tremendous contribution to the worldwide commercial success of Cephalon. On behalf of the board of directors and executive team, I want to express my appreciation for his 15 years of excellent service and leadership in establishing Cephalon as one of the leading biopharmaceutical companies in the world," said Frank Baldino, Jr., Ph.D., chairman and CEO. "Bob built strong global sales and marketing organizations and we remain enthusiastic about our growth opportunities and the future of our company."
Roche serves as a member of the board of directors for Intercept Pharmaceuticals.